Is Avelumab on the market?

Avelumab (Avelumab) is a human IgG1 monoclonal antibody that binds to programmed cell death ligand-1 (PD-L1) to block its interaction with receptors on T cells and antigen-presenting cells. Avelumab was first approved by the U.S. Food and Drug Administration (FDA) on March 23, 2017. In September and December of the same year, avelumab was also approved by the European Medicines Agency (EMA) and Health Canada respectively for the treatment of Merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma, and is sold under the trade name Bavencio.

PD-L1 can be expressed on tumor cells and tumor-infiltrating immune cells, and can help suppress anti-tumor immune responses in the tumor microenvironment. Avelumab binds to PD-L1 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1. This interaction releases the inhibitory effect of PD-L1 on immune responses, leading to the restoration of immune responses, including anti-tumor immune responses. Avelumab has also been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. In syngeneic mouse tumor models, blocking PD-L1 activity resulted in decreased tumor growth.

Avelumab is an emerging cancer treatment drug. The original drug has not yet been marketed in China, so it cannot be included in medical insurance. The price of Avelumab's generic drug, 200mg/10mL per box, may be more than RMB 10,000 per box (the price may fluctuate due to the exchange rate). We are not aware of any Avelumab generics being produced and put on the market. For specific prices and drug details, please consult Yade's medical consultant.